GlaxoSmithKline Biologicals, Rixensart, Belgium.
Expert Rev Vaccines. 2011 Dec;10(12):1709-15. doi: 10.1586/erv.11.151.
Recombinant hepatitis B vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally. Reports of rare HBV infections in blood donors with an imbalance of non-A2 genotype HBV in vaccinated subjects have raised questions about the cross-protection afforded by HBV-A2 vaccines. Infections in HBV vaccinees were asymptomatic and transient, indicating that vaccination prevented clinical disease. Preclinical data demonstrate cross-reactivity and cross-protection by A2 vaccines against non-A2 HBV genotypes. Substantial improvements in HBV control have been demonstrated in countries with diverse genotype distribution that have introduced universal childhood HBV vaccination programs. Available data show that current HBV-A2 vaccines are highly effective in preventing infections and clinical disease caused by all known HBV genotypes.
重组乙型肝炎疫苗为 A2 基因型；已知的十种基因型之一，其分布在全球范围内存在差异。在接种疫苗的受试者中，非 A2 基因型乙型肝炎病毒失衡的血液供体中罕见乙型肝炎病毒感染的报告，引发了对乙型肝炎病毒 A2 疫苗提供的交叉保护作用的质疑。乙型肝炎病毒疫苗接种者的感染无症状且短暂，表明疫苗预防了临床疾病。临床前数据表明 A2 疫苗对非 A2 乙型肝炎病毒基因型具有交叉反应性和交叉保护作用。在具有不同基因型分布的国家，引入了普遍的儿童乙型肝炎病毒疫苗接种计划，乙型肝炎病毒的控制得到了显著改善。现有数据表明，目前的乙型肝炎病毒 A2 疫苗在预防所有已知乙型肝炎病毒基因型引起的感染和临床疾病方面非常有效。
